Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Denise A YardleyNancy PeacockBrooke DanielBetrand AnzDavid C MolthropSonalee K ShroffRobyn YoungAleksander JankovAmy Vander WoudeMythili ShastryJohanna PasekLaura M DeBuskJohn D HainsworthPublished in: Breast cancer research and treatment (2020)
Administration of adjuvant eribulin after neoadjuvant chemotherapy was feasible and well tolerated. The 24-month DFS rate did not reach the study target levels in any of the cohorts and was similar to DFS previously described in these cohorts following neoadjuvant chemotherapy alone.